Search Blog
Categories
May 2017
M T W T F S S
« Apr    
1234567
891011121314
15161718192021
22232425262728
293031  

Tags

Theralase Successfully Achieves Primary and Secondary Objectives for First Three Patients Treated Using Anti-Cancer Technology for Bladder Cancer

Theralase Successfully Achieves Primary and Secondary Objectives for First Three Patients Treated Using Anti-Cancer Technology for Bladder Cancer

Toronto, Ontario (FSCwire) – Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the independent Data and Safety Monitoring Board (“DSMB”) has unanimously decided that the primary and secondary objectives for the first part of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) have successfully been met.

Princess Margaret Cancer Centre, University Health Network (“UHN”), in accordance with the DSMB’s decision, is now recommended to enroll an additional six patients for the second part of the Study, treating them at a therapeutic dose of the PDC (0.70 mg/kg) for NMIBC using its novel Photo Dynamic Therapy (“PDT”) technology.

The DSMB is comprised of three highly regarded, independent uro-oncologists; specifically: Dr. Laurence Klotz of Sunnybrook Health Sciences Centre, Dr. Nathan Perlis of the University of Toronto and Dr. Alexandre Zlotta of Mount Sinai Hospital.

The clinical data on the first three patients was presented by Dr. Michael Jewett, Chair of the Medical and Scientific Advisory Board (“MSAB”).

The PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow localization of the PDC to the NMIBC. The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water via a cystoscope. At this point, a fibre optic assembly, known as a Dosimetry Fibre Optic Cage (“DFOC”) with the ability to both emit and detect laser light, is inserted through the cystoscope, to activate the PDC.

The Study is being used to evaluate TLD-1433 for the: primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy.

The Study was designed to treat 3 patients at an initial dose of the PDC (0.35 mg/kg) and included initial monitoring for 30 days, according to the endpoint criteria above.

The DSMB members have unanimously recommended that the first three patients enrolled and treated in the Study successfully achieved the primary and secondary endpoints of the Study and an additional six patients are now eligible to be enrolled into the Study to be treated at a therapeutic dose of the PDC and monitored for 180 days, according to the endpoint criteria.

Dr. Michael Jewett, uro-oncologist at UHN stated that, “I am delighted that a small Canadian company, such as Theralase, has been able to achieve such significant clinical results and in such a short time span. I look forward to Theralase reporting out on the next six patients using the therapeutic dose.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase thanks the DSMB members for their independent review of the clinical data and their decision that the primary and secondary endpoints for the PDT treatment have successfully been achieved for the first three patients in the Study and their recommendation to continue the Study by enrolling an additional six patients to be treated at the therapeutic dose. Theralase looks forward to successfully reporting out on the performance to the primary and secondary endpoints for the next 6 patients and also the exploratory objective of efficacy of all nine patients, as more clinical data is collected. Theralase has now successfully transformed from a pre-clinical to a clinical oncology organization.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com .

This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White

President & CEO

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225

rwhite@theralase.com

www.theralase.com

To view this press release as a PDF file, click onto the following link:

Maximum News Dissemination by FSCwire. http://www.fscwire.com

Copyright © 2017 Filing Services Canada Inc.

MariMed to Showcase Cannabis Business, Products at the 7th Annual LD Micro Invitational

By MariMed Inc.

LOS ANGELES, CA / ACCESSWIRE / May 26, 2017 / MariMed Inc. (OTCQB: MRMD), will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6, at 1:30 PM PST / 4:30 PM EST. Mr. Jon Levine, CFO of MariMed Advisors, will be highlighting MariMed’s recent achievements, its precision dosed products, and cannabis business services that have shaped some of the nation’s foremost medical cannabis cultivation, production and dispensary facilities. To arrange a meeting with management, please contact Robert Haag at mrmd@irthcommunications.com or 1-866-976-4784.

“This year, not only do we have a record number of companies making their LD Micro debuts, such as MariMed, but a record number of companies presenting for the first time in their company’s history,” stated Mr. Chris Lahiji, President of LD Micro. “LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof.”

The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, Calif., and will feature 180 companies in the small/micro-cap space.

View MariMed’s profile here: https://www.ldmicro.com/profile/MRMD

Profiles powered by LD Micro – News Compliments of Accesswire.

About MariMed (formerly Worlds Online):

MariMed Inc., is an industry leader in the design, development, operation, funding, and optimization of medical cannabis cultivation,production, and dispensary facilities. MariMed’s team has developed five state-of-the-art, regulatory-compliant facilities in three states, with six additional facilities currently under development in two other states. These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. MariMed is on the forefront of precision dosed products for the treatment of specific medical conditions. MariMed branded products are being distributed in three states with distribution being finalized in six additional states. For additional information about MariMed, visit www.MarimedAdvisors.com

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact Mr. David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

MariMed Business Development
Jon Levine, CFO, MariMed Advisors
844-244-0200

Investor Relations
+1-866-976-4784

Media Relations
Julie Shepherd, Accentuate PR
847-275-3643

SOURCE: MariMed Inc.

ReleaseID: 464245

BioVie Inc. to Present at the 7th Annual LD Micro Invitational

By BioVie Inc.

LOS ANGELES, CA / ACCESSWIRE / May 26, 2017 / BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today announced that it will be presenting at the 7th annual LD Micro Invitational on Wednesday, June 7 at 8:30 AM PST / 11:30 AM EST. Jonathan Adams, CEO, will be giving the presentation and will be meeting with investors.

Conference participants who are interested in scheduling a meeting are encouraged to sign up through the conference’s portal, or by calling Tony Schor at 847-945-2222 ext. 221.

BioVie is currently focused on developing and commercializing BIV201, its lead therapeutic candidate and novel approach to the treatment of refractory ascites due to advanced liver cirrhosis. BioVie will soon commence a Phase 2a clinical trial in six of these patients. BIV201 is a continuous ambulatory infusion of the peptide terlipressin and has Orphan drug status and patent protection in the US. Terlipressin, dosed differently, is approved in about 40 countries for other complications of liver cirrhosis arising from a similar disease pathway. Terlipressin is not available in the US and currently there are no FDA-approved drugs specifically for treating ascites which represents a significant unmet medical need.

BIV201 could become the first drug ever approved by the FDA for treating refractory ascites due to liver cirrhosis, a life-threatening condition which affects about 10,000 Americans. The condition results primarily from hepatitis, alcoholism, and nonalcoholic steatohepatitis (NASH) linked to fatty liver disease and obesity. Ascites is a common complication of advanced liver cirrhosis and an estimated 40% of patients die within two years of diagnosis. Certain drugs approved for other uses may provide initial relief, but patients often fail to respond to them as ascites worsens. US treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $4 billion annually.

“This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company’s history” stated Chris Lahiji, President of LD Micro. “LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof.”

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space.

View BioVie Inc. profile here: https://www.ldmicro.com/profile/BIVI

Profiles powered by LD Micro – News Compliments of Accesswire.

About BioVie, Inc.

BioVie Inc. is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In March 2017, BioVie received notification from the FDA that it could initiate a Phase 2a US clinical trial. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. It has Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. For more information about BioVie and BIV201, please visit our website: www.biovieinc.com.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

BioVie Contact:
Tony Schor
Investor Awareness, Inc.
847.945.2222 ext. 221
tony@investorawarenes.com

SOURCE: BioVie Inc.

ReleaseID: 464267

Loan Advisor, a Website that Connects People with a Licensed Moneylender in Singapore, Launches New Site

By Loan Advisor

Thanks to Loan Advisor, People Can Easily Find a Reliable Licensed Money Lender in Singapore

SINGAPORE / ACCESSWIRE / May 26, 2017 / The founders of Loan Advisor, a company that helps match people to a licensed moneylender in Singapore, are pleased to announce the launch of their upgraded website.

To learn more about how Loan Advisor can help people get the personal loan that they need, as well as the three-step process that they use to assist customers in getting the loan, please visit https://www.loanadvisor.sg/.


For people who need a loan, Loan Advisor will help simplify the process in finding a reliable, licensed money lender in Singapore. From families who need money for home repairs to couples who are dealing with a medical or other emergency and need money quickly, Loan Advisor will help them find reliable companies that can assist them.

Using the Loan Advisor website is easy and stress-free; after filling out a simple and quick application form, the website will use the information to match the applicant with the best licensed money lender for his or her needs.

“Customers will get instant loan offers from multiple licensed money lenders in Singapore,” noted a company spokesperson, adding that this service is free and they have made it as quick and easy as possible for people to compare rates from licensed money lenders.

Once applicants have accepted the loan offer they want, they simply need to head down to the licensed money lender’s office to complete the loan process.

As the spokesperson noted, the founders of Loan Advisor understand that applying for a traditional loan from a bank is a lengthy process that typically involves a great deal of paperwork and time. They also know that when people are strapped for cash and need a loan to pay the bills or purchase new tires for the car, they do not have long to wait. This inspired them to launch Loan Advisor, and offer a platform where people can be matched to qualifying moneylenders in Singapore. While they are not a moneylender and do not provide loan services, Loan Advisor is happy to help people find the best moneylender for their needs.

To learn more about the loan comparison website for licensed moneylender loans, please watch a short video on YouTube at https://www.youtube.com/watch?v=RJP0OIGNyqQ.

About Loan Advisor:

Loan Advisor helps match customers to a licensed moneylender in Singapore so as to help them simplify the loan process in finding a reliable loan provider. For more information, please visit https://www.loanadvisor.sg/.

Contact:

Alvin Hines
admin@rocketfactor.com
(949) 555-2861

SOURCE: Loan Advisor

ReleaseID: 464282

Crimson Forest and Hannover House Announce Specifics of First Production with U.K. Based Silver Lining Productions

By Hannover House, Inc.

CANNES, FRANCE / ACCESSWIRE / May 26, 2017 / As buyers, sellers, producers and talent wrap-up activities on the last day of the Cannes Film Festival Marche du Film, U.S. distribution partners Crimson Forest Entertainment Group, Inc. (OTC PINK: CRIM) and Hannover
House, Inc. (OTC PINK: HHSE) have disclosed the first of at least two film production ventures with Silver Lining Productions of London.

“Shimmer” is a live action family-appeal feature about a young boy protecting a Welsh Dragon from nefarious outsiders. The screenplay was written and will be directed by Scott Wheeler, a noted producer and director of science-fiction, fantasy and family films as well as being an acclaimed visual effects master and founder of Rogue State (a U.S.-based post-production facility). Producers will be Grant Bradley (“Singularity”) and Steve Hodges (“Bronte”) along with line producer Erika Steele. Production is slated to occur this summer with principal photography occurring in and around Snowdonia, in Northern Wales. Star casting is now underway.

Executive Producers will include Eric Parkinson, Jonathan Lim and Fred Shefte. Due to the fluid nature of films in a pre-production mode, credits and other production specifics are still subject to potential change.

Crimson Forest and Hannover House have licensed all distribution rights for the USA and English-speaking provinces of Canada for “Shimmer.” A USA theatrical release is planned for Spring 2018.

For more information contact: MaryEvelyn Jones, MeJones@CFF.TV, 479-521-5774

SOURCE: Hannover House, Inc.

ReleaseID: 464311

Theralase Successfully Achieves Primary and Secondary Objectives for First Three Patients Treated Using Anti-Cancer Technology for Bladder Cancer

By Theralase Technologies Inc.

TORONTO, ON / ACCESSWIRE / May 26, 2017 / Theralase Technologies Inc. (“Theralase®” or the “Company“) (TSX-V: TLT) (OTC PINK: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs“) to destroy cancer, announced todaythat the independent Data and Safety Monitoring Board (“DSMB“) has unanimously decided that the primary and secondary objectives for the first part of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC“) clinical study (“Study“) have successfully been met.

Princess Margaret Cancer Centre, University Health Network (“UHN“), in accordance with the DSMB’s decision, is now recommended to enroll an additional six patients for the second part of the Study, treating them at a therapeutic dose of the PDC (0.70 mg/kg) for NMIBC using its novel Photo Dynamic Therapy (“PDT“) technology.

The DSMB is comprised of three highly regarded, independent uro-oncologists; specifically: Dr. Laurence Klotz of Sunnybrook Health Sciences Centre, Dr. Nathan Perlis of the University of Toronto and Dr. Alexandre Zlotta of Mount Sinai Hospital.

The clinical data on the first three patients was presented by Dr. Michael Jewett, Chair of the Medical and Scientific Advisory Board (“MSAB“).

The PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow localization of the PDC to the NMIBC. The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water via a cystoscope. At this point, a fibre optic assembly, known as a Dosimetry Fibre Optic Cage (“DFOC“) with the ability to both emit and detect laser light, is inserted through the cystoscope, to activate the PDC.

The Study is being used to evaluate TLD-1433 for the: primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy.

The Study was designed to treat 3 patients at an initial dose of the PDC (0.35 mg/kg) and included initial monitoring for 30 days, according to the endpoint criteria above.

The DSMB members have unanimously recommended that the first three patients enrolled and treated in the Study successfully achieved the primary and secondary endpoints of the Study and an additional six patients are now eligible to be enrolled into the Study to be treated at a therapeutic dose of the PDC and monitored for 180 days, according to the endpoint criteria.

Dr. Michael Jewett, uro-oncologist at UHN stated that, “I am delighted that a small Canadian company, such as Theralase, has been able to achieve such significant clinical results and in such a short time span. I look forward to Theralase reporting out on the next six patients using the therapeutic dose.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase thanks the DSMB members for their independent review of the clinical data and their decision that the primary and secondary endpoints for the PDT treatment have successfully been achieved for the first three patients in the Study and their recommendation to continue the Study by enrolling an additional six patients to be treated at the therapeutic dose. Theralase looks forward to successfully reporting out on the performance to the primary and secondary endpoints for the next 6 patients and also the exploratory objective of efficacy of all nine patients, as more clinical data is collected. Theralase has now successfully transformed from a pre-clinical to a clinical oncology organization.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company“) (TSX-V: TLT) (OTC PINK: TLTFF) in its Therapeutic Laser Technology (“TLT“) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT“) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs“), which localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may“, “would“, “could“, “should“, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White
President & CEO
|1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 464273

Investor Network: Orion Energy Systems, Inc. to Host Earnings Call

By Investor Network

NEW YORK, NY / ACCESSWIRE / May 26, 2017 / Orion Energy Systems, Inc. (NASDAQ: OESX) will be discussing their earnings results in their Q4 Earnings Call to be held May 26, 2017 at 10:00 AM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/23245.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/23245.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 464251

IIROC Trade Resumption – GoEasy Ltd.

Toronto, Ontario–(Newsfile Corp. – May 26, 2017) – Trading resumes in:

Company:

GoEasy Ltd.

TSX Symbol:

GSY (all issues)

Resumption Time (ET):

08:00

IIROC can make a decision to impose a temporary suspension of trading in a security of a publicly listed company, usually in anticipation of a material news announcement by the company. Trading halts are issued based on the principle that all investors should have the same timely access to important company information. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

– 30 –

For further information: IIROC Inquiries 1-877-442-4322 (Option 3) – Please note that IIROC is not able to provide any additional information regarding a specific trading halt. Information is limited to general enquiries only.

Great Atlantic Resources Closes Financing

Great Atlantic Resources Closes Financing

Vancouver, British Columbia (FSCwire)Great Atlantic Resources Corp. (TSXV: GR) (the “Company” or “Great Atlantic”) is pleased to announce that is has closed the non-brokered private placement previously announced on May 16, 2017 for gross proceeds of $160,000. The units of the financing will be comprised of one common share at a price of $0.08 and a full share purchase warrant, which may be exercised for a period of five years at a price of $0.10 per share. The Company announces September 24, 2017 as the hold period expiry date for this private placement. The Company also announces it has granted 700,000 options at an exercise price of $0.15. The options are exercisable for five years and will be cancelled 30 days after cessation of acting as director, officer, employee or consultant of the Company.

On Behalf of the board of directors

“Lorne Mann”

Director

604-488-3900

This News Release may contain forward-looking statements including but not limited to the Transaction, receipt of property titles, execution of the Option Agreement, the making of cash payments and share payments, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Actual results may differ materially from those currently anticipated in such statements and Great Atlantic undertakes no obligation to update such statements, except as required by law. The reader is cautioned not to place undue reliance on any forward-looking information. There can be no assurance that the proposed Transaction will be completed or, if completed, will be successful.

Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates, including that: the current price of and demand for minerals being targeted by the Company will be sustained or will improve; the Company’s current exploration programs and objectives can be achieved; the Company will be able to obtain required exploration licences and other permits; general business and economic conditions will not change in a material adverse manner; financing will be available if and when needed on reasonable terms; the Company will not experience any material accident; and the Company will be able to identify and acquire additional mineral interests on reasonable terms or at all. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including: that resource exploration and development is a speculative business; that the Company may lose or abandon its property interests or may fail to receive necessary licences and permits; that environmental laws and regulations may become more onerous; that the Company may not be able to raise additional funds when necessary; potential defects in title to the Company’s properties; fluctuations in currency exchange rates; fluctuating prices of commodities; operating hazards and risks; competition; potential inability to find suitable acquisition opportunities and/or complete the same; and other risks and uncertainties listed in the Company’s public filings. These risks, as well as others, could cause actual results and events to vary significantly. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Great Atlantic Resource Corp

888 Dunsmuir Street – Suite 888, Vancouver, B.C., V6C 3K4

To view this press release as a PDF file, click onto the following link:

Maximum News Dissemination by FSCwire. http://www.fscwire.com

Copyright © 2017 Filing Services Canada Inc.

Bearing Files Response to SEC Comments Regarding the F-4 Registration Statement Pursuant to Agreement and Plan of Merger with Li3 Energy Inc. and Provides Update on Settlement of Li3 Notes

Vancouver, British Columbia–(Newsfile Corp. – May 26, 2017) – Bearing Lithium Corp. (TSXV: BRZ) (“Bearing” or the “Company“) is pleased to announce that, on May 24th, 2017, it filed a response to the United Securities and Exchange Commission (the “SEC”) in regards to their comments on the original draft of the Form F-4 Registration Statement. The Registration Statement has been filed with the SEC for the purpose of registering the 16 million common shares of Bearing issuable to the Li3 Energy Inc. (“Li3”) shareholders on closing of the merger Agreement, and is a critical stage in the steps towards closing.

Jeremy Poirier, President and CEO, commented “the filing of Bearing’s response to the SEC’s initial comments on the F-4 registration is an important step towards completing the merger with Li3 Energy. We trust we have addressed the SEC’s concerns adequately and look forward to working constructively with the SEC throughout the review period. We anticipate the next round of comments, if any, within the next ten business days. Once the SEC has approved the document, we look to announce a shareholder vote and finalize the merger in a timely fashion.”

Bearing’s Agreement with Li3 Energy Inc. will enable it to acquire an interest in the advanced-stage Maricunga project located in Chile (the “Maricunga Project“), which represents one of the highest-grade development opportunities in the Americas. Assuming completion of the transaction, Bearing will have an undivided 17.7% interest in the project with all expenditures through to the delivery of a Definitive Feasibility Study (DFS) fully-funded by its joint-venture partners. In excess of US$30 million has been invested in the Maricunga Project to date.

The transactions are subject to customary closing conditions, including the approval of the TSX Venture Exchange and of the shareholders of Li3 and, if required, of Bearing, and the SEC declaring the Registration Statement effective.

In addition, as previously announced on December 7, 2016 and May 15, 2017, Bearing has entered into settlement agreements with the holders of outstanding convertible notes (the “Noteholders“) of Li3. The Company announces that it has now entered into amended and restated settlement agreements (the “Amended and Restated Settlement Agreements“) with the Noteholders. Subject to approval of the TSX Venture Exchange, in accordance with the Amended and Restated Settlement Agreements, the Noteholders have agreed to accept units of Bearing (on the terms previously announced) prior to the closing of the transactions with Li3 in settlement of the outstanding debt owed under the convertible notes. As part of the settlement, the debt owed by Li3 under the convertible notes has been assigned to the Company. All units of Bearing issued on settlement of the convertible notes will be subject to a four month statutory hold period in Canada.

About Bearing Lithium Corp.

Bearing is an exploration and development company. The Li3 Definitive Agreement will enable it to acquire an interest in the advanced-stage Maricunga project located in Chile, which represents one of the highest-grade development opportunities in the Americas. Assuming completion of the transactions contemplated by the Li3 Definitive Agreement, Bearing will have an undivided 17.7% interest in the project with all expenditures through to the delivery of a Definitive Feasibility Study (DFS) fully-funded by its joint-venture partners. The Maricunga Project has had in excess of US$25 million of exploration to date.

ON BEHALF OF THE BOARD

Signed “Jeremy Poirier”
Jeremy Poirier, President and CEO

FOR FURTHER INFORMATION PLEASE CONTACT:
Jeremy Poirier– President and CEO Bearing Lithium – Telephone: 1-604-262-8835

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

This press release includes certain “forward-looking information” and “forward-looking statements”(collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward-looking statements.

Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements in this press release relate to, among other things: completion of the proposed transaction with Li3 and the settlement of the outstanding debt owed to the Li3 Noteholders. Actual future results may differ materially. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the absence of a material adverse change in the Maricunga Property and receipt of all necessary regulatory and shareholder approvals. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times. Except as required by law, Bearing does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.